AU2004280115B2 - Fibrinogen targetting microparticles for promoting haemostasis - Google Patents

Fibrinogen targetting microparticles for promoting haemostasis Download PDF

Info

Publication number
AU2004280115B2
AU2004280115B2 AU2004280115A AU2004280115A AU2004280115B2 AU 2004280115 B2 AU2004280115 B2 AU 2004280115B2 AU 2004280115 A AU2004280115 A AU 2004280115A AU 2004280115 A AU2004280115 A AU 2004280115A AU 2004280115 B2 AU2004280115 B2 AU 2004280115B2
Authority
AU
Australia
Prior art keywords
fibrinogen
product
platelet
platelets
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004280115A
Other languages
English (en)
Other versions
AU2004280115A1 (en
Inventor
Alison Helena Goodall
Sarah Margaret Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haemostatix Ltd
Original Assignee
Haemostatix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haemostatix Ltd filed Critical Haemostatix Ltd
Publication of AU2004280115A1 publication Critical patent/AU2004280115A1/en
Application granted granted Critical
Publication of AU2004280115B2 publication Critical patent/AU2004280115B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2004280115A 2003-10-07 2004-10-07 Fibrinogen targetting microparticles for promoting haemostasis Ceased AU2004280115B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0323378.0A GB0323378D0 (en) 2003-10-07 2003-10-07 Therapeutic agent
GB0323378.0 2003-10-07
PCT/GB2004/004235 WO2005035002A1 (en) 2003-10-07 2004-10-07 Fibrinogen targetting microparticles for promoting haemostasie

Publications (2)

Publication Number Publication Date
AU2004280115A1 AU2004280115A1 (en) 2005-04-21
AU2004280115B2 true AU2004280115B2 (en) 2011-03-24

Family

ID=29415609

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004280115A Ceased AU2004280115B2 (en) 2003-10-07 2004-10-07 Fibrinogen targetting microparticles for promoting haemostasis

Country Status (9)

Country Link
US (1) US20080064628A1 (https=)
EP (1) EP1677829B1 (https=)
JP (2) JP4938454B2 (https=)
CN (1) CN1863560A (https=)
AU (1) AU2004280115B2 (https=)
CA (1) CA2541005C (https=)
GB (1) GB0323378D0 (https=)
IL (1) IL174580A0 (https=)
WO (1) WO2005035002A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0516091D0 (en) * 2005-08-04 2005-09-14 Haemostatix Ltd Therapeutic agent
GB0623607D0 (en) * 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
US9114127B2 (en) * 2007-05-15 2015-08-25 Richard C. K. Yen Biologic devices for hemostasis
KR20100057642A (ko) * 2007-09-11 2010-05-31 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｃｎｐ-２２ 단독 또는 피살라에민과 배합된 이의 용도
WO2009046845A2 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of a lactoferrin partial peptide peptide as a therapeutic agent
GB201101740D0 (en) 2011-02-01 2011-03-16 Haemostatix Ltd Therapeutic agents with improved fibrinogen binding
GB201201751D0 (en) * 2012-02-01 2012-03-14 Haemostatix Ltd Haemostatic wound dressing
GB201204868D0 (en) 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
AU2013334180A1 (en) * 2012-10-25 2015-05-14 The Children's Hospital Of Philadelphia Affinity peptide-modified particles and targeted drug delivery methods
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions
WO2017103914A1 (en) 2015-12-17 2017-06-22 Regentis Biomaterials Ltd. Ready for use organic solvent free compositions comprising protein-polymer conjugates and uses thereof
EP3887404A4 (en) 2018-11-30 2022-11-02 Cellphire, Inc. SLIDES LOADED WITH ANTI-CANCER AGENTS
US11767511B2 (en) 2018-11-30 2023-09-26 Cellphire, Inc. Platelets as delivery agents
AU2020267368B2 (en) 2019-05-03 2023-05-04 Cellphire, Inc. Materials and methods for producing blood products
CN110448719B (zh) * 2019-06-28 2020-05-22 浙江大学 一种促进凝血的丝素-多肽电纺膜及其制备方法
EP4013496A4 (en) 2019-08-16 2023-10-18 Cellphire Inc. THROMBOSOMES AS AN AGENT FOR REMOVING THE THROMBOCYTE AGGREGATION-INHIBITING EFFECT
CA3170201A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Methods of treating congenital hemophilia with anti-fibrinolytic loaded platelets
TW202245814A (zh) 2021-02-17 2022-12-01 美商賽菲爾公司 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物
JP2024539653A (ja) * 2021-10-15 2024-10-29 ノース カロライナ ステート ユニバーシティ 生体液を精製するための組成物及び方法
GB2642384A (en) * 2023-01-31 2026-01-07 Univ North Carolina State Compositions and methods for purifying biological fluids

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0618225A1 (de) * 1993-04-01 1994-10-05 MERCK PATENT GmbH Lineare Adhäsionsinhibitoren
WO1998017319A2 (en) * 1996-10-21 1998-04-30 Quadrant Healthcare (Uk) Limited Platelet substitutes and conjugation methods suitable for their preparation
WO1999025383A1 (en) * 1997-11-14 1999-05-27 Quadrant Healthcare (Uk) Limited Conjugates comprising two active agents
WO1999042146A1 (en) * 1998-02-20 1999-08-26 Quadrant Healthcare (Uk) Limited Products comprising fibrinogen for use in therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5357042A (en) * 1984-04-23 1994-10-18 The General Hospital Corporation Synthetic peptides capable of eliciting fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity
US6391343B1 (en) * 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
PT796090E (pt) * 1994-12-16 2003-07-31 Elan Drug Delivery Ltd Microparticulas reticuladas e sua utilizacao como veiculos terapeuticos
WO2004045542A2 (en) 2002-11-15 2004-06-03 Arizona Board Of Regents Arizona State University Therapeutic bioconjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0618225A1 (de) * 1993-04-01 1994-10-05 MERCK PATENT GmbH Lineare Adhäsionsinhibitoren
WO1998017319A2 (en) * 1996-10-21 1998-04-30 Quadrant Healthcare (Uk) Limited Platelet substitutes and conjugation methods suitable for their preparation
WO1999025383A1 (en) * 1997-11-14 1999-05-27 Quadrant Healthcare (Uk) Limited Conjugates comprising two active agents
WO1999042146A1 (en) * 1998-02-20 1999-08-26 Quadrant Healthcare (Uk) Limited Products comprising fibrinogen for use in therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVIES AR et al. Platelets. 2002. 13(4): 197-205 *
LEVI M et al. Nature Medicine. 1999. 5(1): 107-111 *

Also Published As

Publication number Publication date
CN1863560A (zh) 2006-11-15
EP1677829A1 (en) 2006-07-12
US20080064628A1 (en) 2008-03-13
JP2011184465A (ja) 2011-09-22
JP2007507480A (ja) 2007-03-29
EP1677829B1 (en) 2014-12-24
JP4938454B2 (ja) 2012-05-23
WO2005035002A1 (en) 2005-04-21
CA2541005C (en) 2012-05-08
CA2541005A1 (en) 2005-04-21
GB0323378D0 (en) 2003-11-05
AU2004280115A1 (en) 2005-04-21
IL174580A0 (en) 2006-08-20

Similar Documents

Publication Publication Date Title
AU2004280115B2 (en) Fibrinogen targetting microparticles for promoting haemostasis
JP2007507480A5 (https=)
US20130029913A1 (en) Artificial platelets
Fressinaud et al. Platelet von Willebrand factor: evidence for its involvement in platelet adhesion to collagen
Okamura et al. Hemostatic effects of phospholipid vesicles carrying fibrinogen γ chain dodecapeptide in vitro and in vivo
Takeoka et al. Function of fibrinogen γ-chain dodecapeptide-conjugated latex beads under flow
US20080241233A1 (en) Targeted delivery and expression of procoagulant hemostatic activity
ES2434855T3 (es) Método para la elaboración de fragmentos de trombocitos aglutinables y su utilización
JP6636443B2 (ja) 出血性症候群の場合における失血を制御する及び／又は血小板の代用にすることが可能であるコラーゲンに基づいた注射用製剤
Lee et al. Platelet substitutes and novel platelet products
Minamoto et al. Detection of platelet adhesion/aggregation to immobilized ligands on microbeads by an aggregometer
Danton et al. Monoclonal antibodies to platelet glycoproteins Ib and IIb IIIa inhibit adhesion of platelets to purified solid-phase von Willebrand factor
Mursalimov Peeling Effect of Cells on Fibrinogen Multilayer as an Anti-Adhesive Control Mechanism for Hemostatic Thrombus Formation
Zou et al. Multi-functional platelets: translating biological functions into therapeutic applications
Oorschot The current development of (semi-) artificial platelet substitutes
Miscevic Biologic Properties of Platelet-derived Microparticles: Characterization of Mechanisms of Generation and Adhesion
JP2020508963A (ja) Ｒｍｐ組成物および使用方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ FIBRINOGEN TARGETTING MICROPARTICLES FOR PROMOTING HAEMOSTASIS

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired